Opdualag

Nivolumab dosing is standardized but can vary based on the specific indication and whether it is being used as a single agent or in combination with other drugs. According to the FDA-approved labeling, common adult dosages include:

• Monotherapy (Standard): 240 mg administered every 2 weeks (Q2W) or 480 mg administered every 4 weeks (Q4W) as an intravenous infusion over 30 to 60 minutes.
• Melanoma (Adjuvant): 240 mg Q2W or 480 mg Q4W for up to 1 year.
• Combination with Ipilimumab: In many settings (like RCC or Melanoma), the dose is 1 mg/kg or 3 mg/kg of Nivolumab followed by Ipilimumab on the same day, every 3 weeks for 4 doses, followed by Nivolumab monotherapy (240 mg Q2W or 480 mg Q4W).
• Combination with Chemotherapy: Dosing varies (e.g., 360 mg every 3 weeks) depending on the specific chemotherapy backbone being used.

Nivolumab is approved for pediatric use in specific circumstances, primarily for the treatment of Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer in children aged 12 years and older.

• Pediatric Dose (12 years and older, weighing 40 kg or more): 240 mg every 2 weeks or 480 mg every 4 weeks.
• Pediatric Dose (12 years and older, weighing less than 40 kg): 3 mg/kg every 2 weeks.

Safety and effectiveness in pediatric patients younger than 12 years of age for MSI-H/dMMR colorectal cancer have not been established. For other indications, Nivolumab is generally not approved for pediatric use unless specifically stated by the healthcare provider in a clinical trial setting.

Renal Impairment

Based on population pharmacokinetic analyses, no dose adjustment is required for patients with mild or moderate renal impairment (kidney dysfunction). Data are limited for patients with severe renal impairment (CrCl < 15 mL/min), and these patients should be monitored closely by their oncology team.

Hepatic Impairment

No dose adjustment is recommended for patients with mild hepatic impairment (liver dysfunction). Nivolumab has not been adequately studied in patients with moderate or severe hepatic impairment (Total Bilirubin > 1.5 to 3 times the upper limit of normal). Use in these populations requires extreme caution and frequent monitoring of liver function tests.

Elderly Patients

No overall differences in safety or efficacy have been observed between elderly patients (65 years and older) and younger patients. Therefore, no specific dose adjustments are required based solely on age, although general health status and comorbidities (other health conditions) must be considered.

Nivolumab is not a pill; it must be administered by a healthcare professional in a clinical setting (hospital or infusion center).

• Preparation: The solution should be inspected for particulate matter and discoloration. It should not be shaken. The drug may be infused directly or diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection.
• Infusion: The infusion typically lasts 30 to 60 minutes through an intravenous line containing a sterile, non-pyrogenic, low-protein binding in-line filter (pore size of 0.2 micrometer to 1.2 micrometer).
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. Once prepared, the infusion solution should be used within 24 hours if stored refrigerated or within 8 hours if stored at room temperature.

If you miss an appointment for a Nivolumab infusion, contact your healthcare provider immediately to reschedule. It is critical to maintain the treatment schedule to ensure the maximum effectiveness of the immunotherapy. Because the drug has a long half-life, the medical team will determine the best timing for the next dose to maintain therapeutic levels without increasing the risk of toxicity.

There is no specific information on overdosage with Nivolumab. In the event of an overdose, patients should be closely monitored for signs or symptoms of adverse reactions, particularly immune-mediated reactions, and appropriate supportive treatment should be instituted immediately. Because Nivolumab works by stimulating the immune system, an overdose could theoretically lead to hyper-activation of the immune response.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not attempt to alter your treatment schedule without direct medical guidance from your oncologist.

Because Nivolumab stimulates the immune system, side effects often result from the immune system attacking healthy tissues. The most common side effects reported in clinical trials (occurring in more than 10% of patients) include:

• Fatigue: A profound sense of tiredness or exhaustion that does not always improve with rest. This is the most frequently reported symptom.
• Rash and Pruritus (Itching): Skin reactions are common. The rash may appear as red, itchy bumps or patches.
• Musculoskeletal Pain: Pain in the muscles, bones, or joints.
• Diarrhea: Increased frequency of bowel movements. While common, it must be monitored closely to ensure it does not progress to colitis (inflammation of the colon).
• Nausea and Decreased Appetite: General stomach upset and a reduced desire to eat.
• Cough and Dyspnea (Shortness of Breath): Mild respiratory symptoms are frequent but require evaluation to rule out lung inflammation.
• Upper Respiratory Tract Infection: Symptoms similar to a common cold.

• Endocrinopathies: These include hypothyroidism (underactive thyroid) or hyperthyroidism (overactive thyroid), which can cause changes in energy levels, weight, and heart rate.
• Vomiting: More severe gastrointestinal distress.
• Pyrexia (Fever): Unexplained increases in body temperature.
• Edema: Swelling, particularly in the hands, ankles, or feet.
• Stomatitis: Inflammation or sores in the mouth.
• Dizziness and Neuropathy: Tingling or numbness in the hands and feet.

• Encephalitis: Inflammation of the brain, which can cause confusion, seizures, or personality changes.
• Myocarditis: Inflammation of the heart muscle, leading to chest pain or heart rhythm disturbances.
• Uveitis: Inflammation of the eye, causing redness, pain, or vision changes.
• Myasthenia Gravis: A condition causing muscle weakness, particularly in the face and throat.
• Rhabdomyolysis: The breakdown of muscle tissue that can lead to kidney damage.

> Warning: Stop taking Nivolumab and call your doctor immediately if you experience any of these symptoms. These are often 'immune-mediated' and can be life-threatening if not treated with corticosteroids.

• Immune-Mediated Pneumonitis: Signs include new or worsening cough, chest pain, or shortness of breath. This is inflammation of the lungs.
• Immune-Mediated Colitis: Signs include severe diarrhea (watery, loose, or bloody stools), severe stomach pain, or tenderness.
• Immune-Mediated Hepatitis: Signs include yellowing of the skin or eyes (jaundice), severe nausea, dark urine, or bleeding/bruising more easily than normal.
• Immune-Mediated Endocrinopathies: Signs include extreme fatigue, weight loss or gain, hair loss, feeling cold, constipation, or rapid heart rate. This can affect the thyroid, adrenal glands, or pituitary gland.
• Immune-Mediated Nephritis: Signs include decreased urine output, blood in the urine, or swelling in the ankles.
• Severe Skin Reactions: Signs include a rash with blisters, peeling skin, or sores in the mouth, nose, or throat (potential Stevens-Johnson Syndrome).
• Infusion Reactions: Signs include chills, shaking, itching, flushing, or difficulty breathing during the infusion.

Some side effects of Nivolumab can persist long after the treatment has ended. Immune-mediated endocrinopathies, such as Type 1 Diabetes or permanent thyroid dysfunction, may require lifelong hormone replacement therapy. There are also rare reports of long-term neurological or cardiovascular effects. Because immunotherapy is a relatively new field, researchers are still monitoring patients for potential 'late-onset' immune reactions that may occur months or even years after the final dose.

As of 2024, Nivolumab does not carry a traditional FDA 'Black Box Warning' for monotherapy. However, it carries significant 'Warnings and Precautions' regarding Immune-Mediated Adverse Reactions. When used in combination with other agents like Ipilimumab, the risk and severity of these reactions increase significantly. The labeling emphasizes that early identification and management with high-dose corticosteroids are essential to prevent fatalities.

Report any unusual symptoms to your healthcare provider immediately. Early intervention is the key to managing immunotherapy side effects.

Nivolumab is a potent medication that alters the function of the immune system. While this is necessary to fight cancer, it can cause the immune system to attack any organ or tissue in the body. These reactions can happen at any time during treatment or even after treatment has stopped. It is vital that patients carry a 'Wallet Card' or wear medical alert jewelry indicating they are receiving PD-1 inhibitor therapy so that emergency responders are aware of the risk of immune-mediated reactions.

No FDA black box warnings for Nivolumab monotherapy. However, healthcare providers must be aware of the high incidence of severe immune-related adverse events (irAEs), particularly when Nivolumab is combined with CTLA-4 inhibitors like ipilimumab.

• Immune-Mediated Adverse Reactions: These can occur in the lungs, intestines, liver, endocrine system, kidneys, and skin. Treatment usually involves withholding Nivolumab and starting high-dose corticosteroids (like prednisone). In severe cases, Nivolumab may need to be permanently discontinued.
• Infusion-Related Reactions: Severe infusion reactions have been reported. Patients should be monitored during and for some time after the infusion. If a severe reaction occurs, the infusion must be stopped immediately and permanently.
• Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Patients who receive Nivolumab before or after an allogeneic stem cell transplant are at an increased risk of severe graft-versus-host disease (GVHD) and other transplant-related complications.
• Embryo-Fetal Toxicity: Nivolumab can cause fetal harm when administered to a pregnant woman. It is essential to use effective contraception during treatment and for at least 5 months after the last dose.
• Organ Transplant Rejection: There have been reports of organ transplant rejection (e.g., kidney, liver, heart) in patients treated with PD-1 inhibitors.

Your healthcare provider will require frequent laboratory tests to monitor for silent side effects. These typically include:

• Liver Function Tests (LFTs): Checking levels of ALT, AST, and bilirubin to monitor for hepatitis.
• Thyroid Function Tests (TFTs): Monitoring TSH and Free T4 levels to check for thyroid dysfunction.
• Serum Creatinine: To monitor kidney function and detect nephritis.
• Blood Glucose: To monitor for the development of new-onset Type 1 Diabetes.
• Electrolytes: To check for imbalances caused by adrenal insufficiency or kidney issues.
• Complete Blood Count (CBC): To monitor for rare immune-mediated blood disorders.

Nivolumab generally does not have a direct effect on the ability to drive or operate machinery. However, side effects like fatigue, dizziness, or confusion (if encephalitis occurs) can impair these abilities. Patients should evaluate how they feel after an infusion before attempting to drive or use heavy equipment.

There is no known direct interaction between alcohol and Nivolumab. However, alcohol can exacerbate certain side effects like dehydration, nausea, and liver strain. It is generally recommended to limit alcohol consumption during cancer therapy to maintain overall health and liver function.

Unlike many medications, Nivolumab does not require a 'taper' because it is a large protein with a long half-life that leaves the body slowly. However, if Nivolumab is stopped due to an immune-mediated reaction, the patient will likely be started on a tapering dose of corticosteroids. It is critical to follow the steroid taper exactly as prescribed to prevent the immune reaction from returning.

> Important: Discuss all your medical conditions, especially any history of autoimmune disease (like lupus, Crohn's disease, or rheumatoid arthritis), with your healthcare provider before starting Nivolumab.

There are no absolute drug-drug contraindications listed for Nivolumab in the sense of chemical incompatibility within the body. However, the use of Live Vaccines (such as the MMR, yellow fever, or varicella vaccines) is generally contraindicated during treatment. Because Nivolumab affects the immune system, live vaccines could potentially cause a severe infection or fail to produce an immune response.

• Systemic Corticosteroids (e.g., Prednisone, Dexamethasone): High doses of corticosteroids or other immunosuppressants used before starting Nivolumab should be avoided if possible, as they may interfere with the drug's ability to stimulate an anti-tumor immune response. However, once treatment has started, corticosteroids are the primary treatment for managing immune-mediated side effects and do not appear to diminish the anti-cancer efficacy in that context.
• Other Immunotherapy Agents: Combining Nivolumab with other checkpoint inhibitors (like Ipilimumab) significantly increases the risk of severe immune-mediated reactions. This combination requires intensive monitoring.

• Warfarin and Anticoagulants: While there is no direct metabolic interaction, immune-mediated changes in liver function or platelet counts could theoretically affect bleeding times. Patients on anticoagulants should have their INR monitored closely.
• Thiazide Diuretics: These can affect electrolyte levels, which may complicate the diagnosis of immune-mediated adrenal or kidney issues.

Nivolumab is administered intravenously, so there are no known interactions with specific foods, including grapefruit juice or dairy products. Maintaining a healthy, balanced diet is encouraged to help the body cope with the demands of cancer treatment.

• Echinacea: This herb is often used to 'boost' the immune system. Because Nivolumab already significantly stimulates the immune system, taking Echinacea could theoretically increase the risk of immune-mediated side effects.
• St. John’s Wort: While primarily a concern for drugs metabolized by CYP enzymes (which Nivolumab is not), its use is generally discouraged in cancer patients due to the potential for unforeseen interactions with other supportive medications.
• Immunomodulatory Supplements: Any supplement claiming to alter immune function should be discussed with an oncologist before use.

Nivolumab can interfere with the results of certain diagnostic tests:

• Thyroid Scans: Immune-mediated thyroiditis can cause abnormal uptake on thyroid scans.
• PET Scans: Nivolumab can cause 'pseudoprogression,' where a tumor appears larger on a scan because it is being infiltrated by immune cells, rather than because the cancer is growing. This can lead to false-positive interpretations of disease worsening.

For each major interaction, the mechanism is typically pharmacodynamic (how the drugs affect the body) rather than pharmacokinetic (how the body processes the drug). The clinical consequence is usually an increased risk of toxicity (immune over-activation) or a potential reduction in the drug's efficacy (immune suppression).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

• Severe Hypersensitivity: Nivolumab is absolutely contraindicated in patients who have had a severe, life-threatening allergic reaction (anaphylaxis) to Nivolumab or any of the excipients (inactive ingredients) in the formulation, such as mannitol, pentetic acid, polysorbate 80, sodium chloride, or sodium citrate dihydrate.
• Active, Life-Threatening Autoimmune Disease: In rare cases where an autoimmune condition is currently uncontrolled and life-threatening, the risk of hyper-activating the immune system with Nivolumab may outweigh any potential cancer-fighting benefit.

These conditions require a careful risk-benefit analysis by the oncology team:

• History of Autoimmune Disease: Patients with a history of systemic lupus erythematosus, Crohn's disease, ulcerative colitis, or multiple sclerosis are at a much higher risk of experiencing a severe flare-up of their condition if they take Nivolumab.
• Organ Transplantation: Because Nivolumab stimulates T-cells, it can lead to the rejection of a transplanted organ (kidney, liver, heart, etc.).
• Active Infection: While not a strict contraindication, severe active infections should generally be treated before starting immunotherapy to ensure the immune system is not over-taxed.
• Chronic Lung Disease: Patients with pre-existing interstitial lung disease or radiation pneumonitis are at a higher risk for developing severe immune-mediated pneumonitis.

There is a potential for cross-sensitivity among monoclonal antibodies. Patients who have had a reaction to other PD-1 or PD-L1 inhibitors (such as Pembrolizumab, Atezolizumab, or Durvalumab) should be treated with extreme caution, as they may experience a similar or more severe reaction to Nivolumab.

> Important: Your healthcare provider will evaluate your complete medical history, including any 'hidden' autoimmune markers, before prescribing Nivolumab.

Nivolumab is classified as having embryo-fetal toxicity risk. Based on its mechanism of action and data from animal studies, Nivolumab can cause fetal harm when administered to a pregnant woman. Human IgG4 is known to cross the placental barrier; therefore, Nivolumab has the potential to be transmitted from the mother to the developing fetus. Animal studies have shown that PD-1 pathway blockade can lead to an increased risk of immune-mediated rejection of the developing fetus, resulting in fetal death.

• Contraception: Females of reproductive potential should use effective contraception during treatment and for at least 5 months following the last dose of Nivolumab.
• Pregnancy Testing: Healthcare providers typically verify pregnancy status in females of reproductive potential prior to initiating treatment.

It is not known whether Nivolumab is excreted in human milk. Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women are advised not to breastfeed during treatment and for at least 5 months after the last dose. While IgG is present in human milk, it is generally thought to be degraded in the infant's digestive tract; however, the systemic exposure risk to the infant remains a clinical concern.

As previously noted, Nivolumab is approved for pediatric patients aged 12 years and older specifically for MSI-H or dMMR metastatic colorectal cancer. For this population, the safety profile is generally similar to that seen in adults. However, the long-term effects of PD-1 inhibition on the developing immune system of a child are not fully understood. Nivolumab is not currently approved for most other pediatric cancers outside of clinical trials.

Clinical studies of Nivolumab did not include sufficient numbers of patients younger than 65 to determine whether they respond differently than older patients. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. No dosage adjustment is required for geriatric patients, but they should be monitored closely for comorbidities and polypharmacy (the use of multiple medications) which may complicate the management of side effects.

No dose adjustment is recommended for patients with mild to moderate renal impairment. For patients with severe renal impairment (calculated creatinine clearance less than 15 mL/min), there is insufficient data to make a formal recommendation. In these cases, the drug is used with caution, and kidney function is monitored at every infusion cycle.

For patients with mild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and AST greater than ULN, or total bilirubin greater than 1.0 to 1.5 times ULN and any AST), no dose adjustment is necessary. Nivolumab has not been studied in patients with moderate or severe hepatic impairment, and its use is generally not recommended in these populations unless the potential benefit outweighs the risk.

> Important: Special populations require individualized medical assessment and often more frequent laboratory monitoring.

Nivolumab is a human monoclonal antibody that binds to the Programmed Death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. PD-1 is a negative regulator of T-cell activity that is involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed on antigen-presenting cells and may be expressed by tumors or other cells in the tumor microenvironment, results in inhibition of T-cell proliferation and cytokine production. Nivolumab upregulates T-cell responses, including anti-tumor responses, by blocking PD-1 binding to PD-L1 and PD-L2 ligands.

Nivolumab exhibits a dose-dependent occupancy of the PD-1 receptor. In clinical studies, PD-1 receptor occupancy was maintained at levels greater than 70% at doses of 0.3 mg/kg or higher. The duration of this effect is long, consistent with its 25-day half-life. There is no evidence of tolerance development (where the drug becomes less effective over time) in terms of receptor binding affinity.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | Not applicable (Monoclonal antibody) |

| Half-life | ~25 days |

| Tmax | End of infusion (30-60 mins) |

| Metabolism | Protein catabolism (not CYP-mediated) |

| Excretion | Not renally/fecally excreted as intact drug |

• Molecular Formula: C6392H9902N1714O2012S42 (approximate for the heavy and light chains)
• Molecular Weight: Approximately 146,000 Daltons (146 kDa)
• Solubility: Soluble in aqueous buffers at physiological pH
• Structure: Nivolumab is a Chinese Hamster Ovary (CHO) cell-derived recombinant human IgG4 monoclonal antibody. It consists of two identical heavy chains and two identical light chains linked by disulfide bonds.

Nivolumab is a PD-1 blocking antibody within the broader therapeutic class of Antineoplastic Agents, Monoclonal Antibodies. It is specifically categorized as an Immune Checkpoint Inhibitor. Related medications include Pembrolizumab (Keytruda), Cemiplimab (Libtayo), and Dostarlimab (Jemperli).